BI-3231, an enzymatic inhibitor of HSD17B13, reduces lipotoxic effects induced by palmitic acid in murine and human hepatocytes
American Journal of Physiology-Cell Physiology · 2024
DOI: 10.1152/ajpcell.00413.2023 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Physiology-Cell Physiology, 2024. Verfasst von Lucia Alcober-Boquet und 13 weiteren Autor:innen. Beteiligte Einrichtung: Medical Clinic 1, Goethe University Frankfurt, University Hospital, Frankfurt, Germany. Hauptthemen laut MEDLINE: Palmitic Acid, Fatty Liver. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Landes-Offensive zur Entwicklung Wissenschaftlich-ökonomischer Exzellenz, EnABLE Cluster, SFB1177.
Abstract (Originalsprache)
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) is a lipid droplet protein primarily expressed in the liver hepatocytes. HSD17B13 is associated with the clinical outcome of chronic liver diseases and is therefore a target for the development of drugs. Here, we demonstrate the promising therapeutic effect of BI-3231 as a potent inhibitor of HSD17B13 based on its ability to inhibit triglyceride accumulation in lipid droplets (LDs), restore lipid metabolism and homeostasis, and increase mitochondrial activity in vitro.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Clinic 1, Goethe University Frankfurt, University Hospital, Frankfurt, Germany.
- Faculty of Medicine, Institute of Pharmacology and Toxicology, Goethe University Frankfurt, Frankfurt, Germany.
- Faculty of Medicine, Institute of Biochemistry I, Goethe University Frankfurt, Frankfurt, Germany.
- Faculty of Medicine, Institute of Clinical Pharmacology, Goethe University Frankfurt, Frankfurt, Germany.
- Faculty of Medicine, Institute of Cardiovascular Regeneration, Goethe University Frankfurt, Frankfurt, Germany.
- Department of Internal Medicine B, University Hospital Münster, Münster, Germany.
ORCID-Profile: Nico Kraus, Liliana Schaefer, Jonel Trebicka, Christoph Welsch, Cristina Ortiz
Förderung
- Landes-Offensive zur Entwicklung Wissenschaftlich-ökonomischer Exzellenz
- EnABLE Cluster
- SFB1177
- SFB1039
- SFB 1177
- SFB 1039
- Landes-Offensive zur Entwicklung Wissenschaftlich-ökonomischer Exzellenz (LOEWE) of the State of Hessen
Zitieren
APA
Alcober-Boquet, L., Kraus, N., Huber, L. S., Vutukuri, R., Fuhrmann, D. C., Stross, C., Schaefer, L., Scholich, K., Zeuzem, S., Piiper, A., Schulz, M. H., Trebicka, J., Welsch, C., & Ortiz, C. (2024). BI-3231, an enzymatic inhibitor of HSD17B13, reduces lipotoxic effects induced by palmitic acid in murine and human hepatocytes. American Journal of Physiology-Cell Physiology. https://doi.org/10.1152/ajpcell.00413.2023
Vancouver
Alcober-Boquet L, Kraus N, Huber LS, Vutukuri R, Fuhrmann DC, Stross C, et al. BI-3231, an enzymatic inhibitor of HSD17B13, reduces lipotoxic effects induced by palmitic acid in murine and human hepatocytes. American Journal of Physiology-Cell Physiology. 2024. doi:10.1152/ajpcell.00413.2023
BibTeX
@article{AlcoberBoquet2024,
author = {Alcober-Boquet, Lucia and Kraus, Nico and Huber, Lisa Sophie and Vutukuri, Rajkumar and Fuhrmann, Dominik C and Stross, Claudia and Schaefer, Liliana and Scholich, Klaus and Zeuzem, Stefan and Piiper, Albrecht and Schulz, Marcel H and Trebicka, Jonel and Welsch, Christoph and Ortiz, Cristina},
title = {BI-3231, an enzymatic inhibitor of HSD17B13, reduces lipotoxic effects induced by palmitic acid in murine and human hepatocytes},
journal = {American Journal of Physiology-Cell Physiology},
year = {2024},
doi = {10.1152/ajpcell.00413.2023}
}
EUVIMED